Pasar al contenido principal

ESTRATEGIA ANTIMICROBIANA INNOVADORA PARA EL TRATAMIENTO DE INFECCIONES BACTERIANAS MULTIRRESISTENTES

PID2022-136357OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD PABLO DE OLAVIDE, DE SEVILLA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Discovery of new antimicrobial thiophene derivatives with activity against drug-resistant Gram negative-bacteria

  • Molina Panadero, Irene
  • Morales-Tenorio, Marcos
  • García-Rubia, Alfonso
  • Ginex, Tiziana
  • Eskandari, Khalil
  • Martínez Gil, Ana
  • Smani, Younes
Our aim is to identify new small molecules with antimicrobial potential, especially against colistin-resistant (Col-R) Acinetobacter baumannii and Escherichia coli. After initial hits identification by fingerprint similarity, MIC of 24 heterocyclic derivatives for A. baumannii and E. coli reference strains, and bactericidal activity of selected thiophenes against Col-R strains were determined. We analyzed changes in bacterial membrane permeability and the OMPs profile. Additionally, we determined bacterial adherence to host cells and performed molecular docking studies to assess their binding to bacterial targets. The compounds’ MICs ranged from 4 to >64 mg/L. Thiophene derivatives 4, 5 and 8 exhibited MIC50 values between 16 and 32 mg/L for Col-R A. baumannii and 8 and 32 mg/L for Col-R E. coli. The time-kill curve assay demonstrated that thiophenes 4 and 8 had bactericidal effects against Col-R A. baumannii and E. coli. Furthermore, treatment with them resulted in increased membrane permeabilization and reduced adherence of these isolates to host cells. Finally, the docking studies showed a stronger binding affinity to CarO1 and Omp33 of A. baumannii and OmpW and OmpC of E. coli. These findings indicate that thiophene derivatives possess antibacterial activity against Col-R A. baumannii and E. coli, suggesting that they may enhance the repertoire of drug treatments against bacteria., This work was funded by the Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación, Fondo Europeo de Desarrollo Regional, MCIN/AEI/10.13039/501100011033/FEDER, UE (grant PID2022-136357OB-I00), the Consejería de Universidad, Investigación e Innovación de la Junta de Andalucía (grant ProyExcel_00116), and the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad (grant PI19/01009), cofinanced by the European Development Regional Fund (A way to achieve Europe, Operative Program Intelligent Growth, 2014–2020). This research work was also funded by the European Commission–NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global). MM-T holds a pre-doctoral FPU grant (FPU18/03493) from MICINN., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Antibacterial activity of tamoxifen derivatives against methicillin-resistant Staphylococcus aureus

  • Molina Panadero, Irene
  • Falcón Torres, Javier
  • Hmadcha, Abdelkrim
  • Princiotto, Salvatore
  • Cutarella, Luigi
  • Mori, Mattia
© 2025 Molina Panadero, Falcón Torres, Hmadcha, Princiotto, Cutarella, Mori, Dallavalle, Christodoulou and Smani., The development of new antimicrobial therapeutic strategies requires urgent attention to prevent the tens of millions of deaths predicted to occur by 2050 as a result of multidrug-resistant (MDR) bacterial infections. This study aimed to discover new tamoxifen derivatives with antimicrobial potential, particularly targeting methicillin-resistant Staphylococcus aureus (MRSA). The minimum inhibitory concentration (MIC) of 22 tamoxifen derivatives was determined against S. aureus reference and MRSA strains using microdilution assays. The antibacterial effects of selected tamoxifen derivatives against MRSA (USA7 strain) were assessed through bacterial growth assays. Additionally, bacterial membrane permeability and molecular dynamics (MD) simulation assays were performed. The MIC of the tamoxifen derivatives against reference S. aureus and MRSA strains ranged from to 16 to >64 μg/mL. Bacterial growth assays demonstrated that tamoxifen derivatives 2, 5, and 6, the only compounds bearing the electron-donating hydroxyl group in the para position on both phenyl rings of the tamoxifen skeleton, dose-dependently reduced the growth of the USA7 strain. Moreover, treatment of MRSA with derivatives 2 and 5 resulted in a slight increase of membrane permeabilization. Extensive MD simulations on the interaction between 5 and 6 and the S. aureus membrane model suggest that the compounds do not act by destabilizing the membrane integrity. These findings suggest that tamoxifen derivatives exhibit antibacterial activity against MRSA, potentially broadening the spectrum of available drug treatments for combating antimicrobial-resistant S. aureus., This work was funded by the Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación, Fondo Europeo de Desarrollo Regional, MCIN/AEI/10.13039/501100011033/FEDER, and (Grant CEX2020-001088-M-20-5) UE (grant PID2022-136357OB-I00), the Consejería de Universidad, Investigación e Innovación de la Junta de Andalucía (grant ProyExcel_00116), and the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad (grant PI19/01009), cofinanced by the European Development Regional Fund (A way to achieve Europe, Operative Program Intelligent Growth, 2014–2020). This study has also received funding from the EU’s NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (project no. PE00000007, INF-ACT) (MM, LC)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2020-001088-M-20-5)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ENOblock synergizes with colistin to treat Acinetobacter baumannii infections

  • Molina Panadero, Irene
  • Moreno Rodríguez, Antonio
  • Rey Hidalgo, Angela
  • de la Cruz, Mercedes
  • Sánchez, Pilar
  • Tomás-Gallardo, Laura
  • Samernate, Thanadon
  • Sencanski, Milan
  • Glisic, Sanja
  • Genilloud, Olga
  • Nonejuie, Poochit
  • Pérez-Pulido, Antonio J.
  • Hmadcha, Abdelkrim
  • Smani, Younes
High-throughput screening studies provide an additional approach to discovering repurposed drugs for antimicrobial treatments. In this work, we report the identification of ENOblock, an anticancer drug, as an antimicrobial agent. We computationally and experimentally validated that ENOblock synergizes with colistin, the last resort antibiotic. Additionally, we identified enolase as the potential bacterial target for ENOblock. The in silico and in vitro antibacterial activity of ENOblock translated into potent in vivo efficacy in an animal infection model. Collectively, the preclinical data support the selection of ENOblock as a promising candidate for antimicrobial development, with the potential to address the urgent threat of infections caused by Acinetobacter baumannii., This research was funded by the Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación, Fondo Europeo de Desarrollo Regional, MCIN/AEI/10.13039/501100011033/FEDER, UE (Grant PID2022-136357OBI00), and (Grant CEX2020-001088-M-20-5), by the Consejería de Universidad, Investigación e Innovación de la Junta de Andalucía (Grant ProyExcel_00116), by the National Research Council of Thailand (NRCT) and Mahidol University: N42A650368, and by the Ministry of Science, Technological Development and Innovation of the Republic of Serbia (Grant number 451-03-136/2025-03/200017). We acknowledge EU-OPENSCREEN ERIC for providing its compound collection and Fundación MEDINA HTS antimicrobial screening platform to support the discovery of the antibacterial activity of the compound described in the presented work. This article is based upon work from COST Action EURESTOP, CA21145, supported by COST (European Cooperation in Science and Technology). AMR is supported by a doctoral fellowship PRE2022-104318, from the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2020-001088-M-20-5)., Peer reviewed